China Seen As The Prize In The Race For HCV Dominance
This article was originally published in PharmAsia News
Executive Summary
As Gilead and AbbVie battle for new hepatitis C treatment options, Roche is hoping a trailing product can find a home in China, where genotype 1b HCV is most prevalent.
You may also be interested in...
Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected
Company also updates Phase II ELECTRON data from November, showing all nine patients in a null-responder cohort achieved sustained virological response after four weeks of therapy with combo.
Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.